Influence of trial duration on the bias of the estimated treatment effect in clinical trials when individual heterogeneity is ignored

DOI10.1002/bimj.201400046zbMath1325.62195OpenAlexW1948419113WikidataQ41568232 ScholiaQ41568232MaRDI QIDQ5257926

Elsa Cécilia-Joseph, Bertran Auvert, Thierry Moreau, Philippe Broët

Publication date: 24 June 2015

Published in: Biometrical Journal (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1002/bimj.201400046

zbMATH Keywords

heterogeneityclinical trialsfrailtyCox modelomitted covariates

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical epidemiology (92C60)

Related Items (1)

BAGS: A Bayesian Adaptive Group Sequential Trial Design With Subgroup-Specific Survival Comparisons

Uses Software

• invGauss

Cites Work

• Unnamed Item
• On proportional hazards assumption under the random effects models
• Survival and event history analysis. A process point of view
• Maximum penalized likelihood estimation in a Gamma-frailty model
• Analysis of multivariate survival data
• Robust inference for univariate proportional hazards frailty regression models
• The unobserved heterogeneity distribution in duration analysis
• Biased estimates of treatment effect in randomized experiments with nonlinear regressions and omitted covariates
• Misspecified proportional hazard models
• Effect of Frailty on Marginal Regression Estimates in Survival Analysis
• Estimation of Variance in Cox's Regression Model with Shared Gamma Frailties
• Assessing the Sensitivity of Regression Results to Unmeasured Confounders in Observational Studies
• Bias and Sensitivity Analysis When Estimating Treatment Effects from the Cox Model with Omitted Covariates
• Estimating average regression effect under non-proportional hazards

This page was built for publication: Influence of trial duration on the bias of the estimated treatment effect in clinical trials when individual heterogeneity is ignored